一分钟看懂
这是一项关于小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括Obrixtamig；ZL-1310；Atezolizumab，当前状态为尚未开始招募。登记地点显示中国南宁、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Obrixtamig；ZL-1310；Atezolizumab · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记摘要未单独列出可展示的排除条件，请查看英文原文并向研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Affiliated Cancer Hospital, Guangxi Medical University · 南宁
- Shanghai Chest Hospital · 上海
- Shanghai Pulmonary Hospital · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- Inclusion criteria:
- For Part 1
- 1. Diagnosed with locally advanced, metastatic or relapsed cancer of the following histologies:
- Small cell lung carcinoma (SCLC)
- Large cell neuroendocrine lung carcinoma (LCNEC-L)
- Extrapulmonary neuroendocrine carcinoma (epNEC) of small or large cell histology
- 2. Patients with tumours with mixed histologies for any above type are eligible only if the neuroendocrine carcinoma/small cell component is predominant and represents at least 50% of the overall tumour tissue
- 3. Patients for whom no therapy of proven efficacy exists or who are not eligible for established treatment options. Patients must have exhausted available treatment options known to prolong survival for their disease. Previous therapies should include at least one line of platinum-based chemotherapy, unless there is a documented medical reason not to use platinum
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07707895；登记信息更新于 2026-09-29；本站同步于 2026-10-08，中国中心当前名额未经人工确认。